<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04596007</url>
  </required_header>
  <id_info>
    <org_study_id>HEC83518-P-01 / CRC-C1934</org_study_id>
    <nct_id>NCT04596007</nct_id>
  </id_info>
  <brief_title>The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC83518 Tablets in Chinses Healthy Subjects</brief_title>
  <official_title>A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HEC83518 Tablets in Chinses Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC83518 Tablets in&#xD;
      Chinses Healthy Subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">September 10, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>All are double-blind except the pre-trial group</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Adverse Events (AEs)</measure>
    <time_frame>up to 5 days</time_frame>
    <description>Safety and Tolerability of HEC83518 by Assessment of the Number of Adverse Events (AEs) Following Administration in Single Ascending Dose .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters - AUC0-∞</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>area under the concentration versus time curve (AUC) from time zero to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters - Cmax</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>Geometric Mean of Maximum Observed Plasma Concentration of HEC83518</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters -tmax</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>time to peak</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters -t½</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>apparent terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters -Vz/F</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>apparent volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters - MRT</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>the Mean Residence Time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters -CL/F</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>the Apparent Clearance</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The pharmacodynamics of HEC83518 tablets</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>The pharmacodynamics of HEC83518 was preliminarily explored through KSS (Karolinska sleepiness Scale, Karolinska Sleepiness Scale) and sleep monitoring instrument</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>HEC83518 tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>There will be a total of 7 dose cohorts: 5 mg,10 mg, 20 mg, 40 mg, 80 mg, and 140 mg,200 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo tablets</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>There will be a total of 6 dose cohorts: 10 mg, 20 mg, 40 mg, 80 mg, and 140 mg,200 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HEC83518 tablets</intervention_name>
    <description>Each dose of HEC83518 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.</description>
    <arm_group_label>HEC83518 tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who are willing and are able to provide a written informed consent to&#xD;
             participate in the study.&#xD;
&#xD;
          2. Without Plann for pregnancy or pregnant within 3 months after enrollment throughout&#xD;
             the trial.&#xD;
&#xD;
          3. Subjects aged between 18 and 45 (both inclusive) years old.&#xD;
&#xD;
          4. Healthy volunteers has a body weight ≥50 kg (for male) or ≥ 45kg (for female) and body&#xD;
             mass index ≥18 and ≤28 kg/m2 at screening.&#xD;
&#xD;
          5. Subjects, who are healthy, as having no clinically significant abnormalities in vital&#xD;
             signs, physical examination, clinical laboratory test results, Chest X-ray and 12-lead&#xD;
             electrocardiogram (ECG).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with a positive serology for human immunodeficiency virus (HIV) antibodies,&#xD;
             hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies and/or TP&#xD;
             antibodies at screening.&#xD;
&#xD;
          2. Subjects with history of digestive system,urinary system, liver,central nervous&#xD;
             system, blood system, endocrine system,respiratory system,immune system,cardiovascular&#xD;
             system,and/or malignant tumor or others medical conditions (such as history of mental&#xD;
             illness, etc.) that are not suitable for clinical trial participation;Subjects with&#xD;
             history of stroke, epilepsy, bipolar disorder/mania, high intraocular pressure, or&#xD;
             acute angular-closure glaucoma.&#xD;
&#xD;
          3. Subjects with history of sleep-related illness.&#xD;
&#xD;
          4. Subjects with history of severe involuntary hypoglycemia&#xD;
&#xD;
          5. Known allergic reactions or hypersensitivity to any excipient of the drug&#xD;
             formulation(s) ,or anaphylaxis physique.&#xD;
&#xD;
          6. Use of any prescription or non-prescription medications within 14 days prior to&#xD;
             initial dosing,or Use of any medications known to inhibit or induce cytochrome P&#xD;
             enzyme drug metabolism within 28 days prior to initial dosing.&#xD;
&#xD;
          7. Consume foods or beverages containing caffeine, xanthine, alcohol, and grapefruit&#xD;
             within 48 hours prior to initial dosing.&#xD;
&#xD;
          8. Positive results from urine drug screen test.&#xD;
&#xD;
          9. History of alcoholism or drink regularly within 3 months prior to the study(defined as&#xD;
             Alcohol consumption of &gt; 21 units/week), or positive results from alcohol breath test.&#xD;
&#xD;
         10. Regular smoking of more than 10 cigarettes per day within 3 months before&#xD;
             administration of study drug.&#xD;
&#xD;
         11. Donate blood or lose blood 400 mL or more within 1 month prior to initial dosing.&#xD;
&#xD;
         12. Subjects who plan to receive or have had organ transplants.&#xD;
&#xD;
         13. Females who are lactating/breastfeeding, or positive result from pregnancy test for&#xD;
             women of child-bearing potential.&#xD;
&#xD;
         14. Subjects who participated in another clinical trial within 3 months prior to initial&#xD;
             dosing.&#xD;
&#xD;
         15. Any other condition with in the opinion of the investigator would render the patient&#xD;
             unsuitable for inclusion in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>YanMei Liu, MS</last_name>
    <phone>021-54030254</phone>
    <email>ymliu@shxh-centerlab.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Shanghai xuhui district central hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YanMei Liu, Doctor</last_name>
      <phone>021-54030254</phone>
      <email>ymliu@shxh-centerlab.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

